Table. 1.

Table. 1.

Demographic and clinical characteristics of patients with febrile neutropenic episodes at the beginning of second-line treatment

PIPC/TAZ (n=48) MEPM (n=36) P-value
Sex (M/F) 26/22 17/19 0.660
Age (median, range) 10.9 (0.5-25.4) 13.55 (0.4-23.7) 0.658
Concomitant IVIG 0.124
Yes/No 26/22 13/23
Disease 0.316
ALL (%) 19 (39.6) 18 (50.0)
AML (%) 13 (27.1) 3 (8.3)
NHL (%) 7 (14.6) 8 (22.2)
Solid tumor (%) 3 (6.3) 3 (8.3)
AA (%) 3 (6.3) 1 (2.8)
Other (%) 3 (6.3) 3 (8.3)
Stem cell transplantation (yes) (%) 9 (18.8) 8 (22.2) 0.786
CV catheter (yes) (%) 47 (97.9) 35 (97.2) 1.000
WBC at the beginning of treatment (×109/L, median, range) 0.28 (0.01-2.00) 0.26 (0.01-14.00) 0.553
CRP at entry (mg/dL, median, range) 3.84 (0.05-29.96) 3.93 (0.05-15.98) 0.845
β-D glucan (pg/mL, range) 6.9 (1.6-53.2) 8.9 (1.9-20.9) 0.172
Procalcitonin (ng/mL, range) 0.23 (0.03-51.03) 0.25 (0.04-46.63) 0.863
IgG (mg/dL, range) 673 (247-1502) 673 (59-1255) 0.970

M, male; F, female; IVIG, intravenous immunoglobulin; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; AA, aplastic anemia; CV, central venous; WBC, white blood cell count; CRP, C-reactive protein; IgG, immunoglobulin G.

Clin Pediatr Hematol Oncol 2021;28:75-83
© 2021 Clin Pediatr Hematol Oncol